Smith & Nephew plc ADR(SNN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | 20.52 | EPS (ttm) | 1.47 | Insider Own | 0.06% | Shs Outstand | 424.7M | Perf Week | 2.66% |
| Market Cap | 12.60B | Forward P/E | 12.6 | EPS next Y | 8.91% | Insider Trans | - | Shs Float | 418.3M | Perf Month | 11.15% |
| Enterprise Value | 15.65B | PEG | 1.34 | EPS next Q | 0.53 | Inst Own | 13.46% | Short Float | 0.97% | Perf Quarter | -7.84% |
| Income | 0.63B | P/S | 2 | EPS this Y | 7.52% | Inst Trans | -6.3% | Short Ratio | 2.63 | Perf Half Y | -3.15% |
| Sales | 6.29B | P/B | 2.45 | EPS next 5Y | 9.41% | ROA | 5.82% | Short Interest | 4.04M | Perf YTD | -8.26% |
| Book/sh | 12.26 | P/C | 16.62 | EPS past 3/5Y | 41.4% 6.97% | ROE | 11.8% | 52W High | -18.85% ($37.09) | Perf Year | -17.94% |
| Cash/sh | 1.81 | P/FCF | 14.83 | Sales past 3/5Y | 5.84% 6.1% | ROIC | 7.51% | 52W Low | 15.24% ($26.12) | Perf 3Y | 39.09% |
| Dividend Est. | $0.78 (2.6%) | EV/EBITDA | 9.37 | EPS Y/Y TTM | 31.02% | Gross Margin | 68.21% | Volatility(W/M) | 1.89% 1.6% | Perf 5Y | -15.24% |
| Dividend TTM | 0.79 | EV/Sales | 2.49 | Sales Y/Y TTM | 5.26% | Oper. Margin | 17.05% | ATR (14) | 0.57 | Perf 10Y | 2.28% |
| Dividend Ex-Date | 2026/10/2 | Quick Ratio | 1.11 | EPS Q/Q | 4.72% | Profit Margin | 10.08% | RSI (14) | 65.31 | Recom | 3 |
| Dividend Gr. 3/5Y | 0.91% 0.54% | Current Ratio | 2.14 | Sales Q/Q | 3.61% | SMA20 | 6.35% ($28.3) | Beta | 0.56 | Target Price | $31.81 |
| Payout | 52.04% | Debt/Eq | 0.73 | Earnings | 2026/8/4 | SMA50 | 6.43% ($28.28) | Rel Volume | 0.56 | Prev Close | $30.47 |
| Employees | 18362 | LT Debt/Eq | 0.62 | EPS/Sales Surpr. | 0.72% -10.44% | SMA200 | -3.24% ($31.11) | Avg Volume(3M) | 1.54M | Price | $30.1 |
| IPO | 1999/11/16 | Option/Short | Yes/Yes | Trades | 4945 | Volume | 852,924 | Change | -1.21% |
A global medical device company headquartered in the UK, specializing in orthopedic implants such as artificial joints, sports medicine devices, and wound care products, listed on the US market in ADR form.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
Traded less than usual. That is 56% of its average volume.
SNN makes money exceptionally well
Of every $100 in sales, $17.05 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +7.5% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company expected to earn $100 next year, you would pay $1,260. Peers typically go for $1,844.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -15.2%. The S&P 500 did +70% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 2.60% annually in dividends.
Tap to view numbers
Ownership is about average
Institutions hold 13.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #12 of 142 in the industry
Based on market cap of $13B.
PEN#11 Penumbra Inc $13B PER 79.6 SNN#12 Smith & Nephew plc ADR $13B PER 20.5 
GMED#13 Globus Medical Inc $11B PER 20.7 
GKOS#14 Glaukos Corp $11B PER - 
PODD#15 Insulet Corp $10B PER 29.7 
FAQ
What kind of company is SNN?
SNN belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of SNN?
The market cap of SNN is approximately $12.6B, ranking 797 within its sector.
Does SNN pay dividends?
SNN has a dividend yield of approximately 2.60%, with an annual dividend of $0.78.
What is the P/E ratio of SNN?
SNN has a P/E ratio of approximately 20.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for SNN?
SNN has recorded a 52-week high of $37.09 and a low of $26.12.
